HPLC–UV assay for the evaluation of inhibitors of plasma amine oxidase using crude bovine plasma

Kira Mergemeier, Florian Galster and Matthias Lehr

Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany

ABSTRACT
Recently, we have described a method for evaluation of plasma amine oxidase (PAO) inhibitors, which monitors the formation of 6-(5-phenyl-2H-tetrazol-2-yl)hexanal from the corresponding amine substrate by HPLC with UV-detection using purified bovine PAO. We now investigated, whether crude bovine plasma can be used as enzyme source in this assay instead of the purified enzyme. With the aid of specific inhibitors, it was ensured that there was no detectable activity of other important amine oxidases in the plasma, namely monoamine oxidase (MAO) A and B and diamine oxidase (DAO). For a series of ω-(5-phenyl-2H-tetrazol-2-yl)alkan-1-amine substrates similar conversion rates were measured for both the purified PAO and crude plasma. The inhibition values determined for the PAO inhibitor 2-(4-phenylphenyl)acetohydrazide (16) under different conditions also corresponded. Additionally, inhibition data of the known PAO inhibitor 2-amino-N-(3-phenylbenzyl)acetamide (17) and a newly synthesised meta-substituted derivative of 16 were determined, which together reflect the two-step inhibition mechanism of these covalent inhibitors.

Introduction
Plasma amine oxidase (PAO) is a totophaquinone- and copper-dependent oxidase, which converts primary amines to aldehydes with the concomitant production of ammonia and hydrogen peroxide. The enzyme, which is also known as copper-containing amine oxidase 3 (AOC3), semicarbazide-sensitive amine oxidase (SSAO) or vascular adhesion protein-1 (VAP-1), is mainly expressed in endothelial cells of blood vessels, smooth muscle cells, and adipocytes. Besides, a soluble form is found in blood plasma, resulting from proteolytic cleavage of membrane-bound vascular PAO. The enzyme participates in several physiological and pathophysiological processes. In particular, it functions as a vascular adhesion protein that mediates recruitment and extravasation of leukocytes at sites of inflammation. Furthermore, it is involved in glucose transport in adipose cells. Because of the production of reactive aldehydes and hydrogen peroxide, PAO activity is linked to cellular damage in diabetes. Thus, inhibitors of this enzyme could be of therapeutic value in the treatment of inflammatory diseases and diabetic complications.

For the determination of activity of PAO and for screening of inhibitors of the enzyme, a variety of methods have been reported. Mostly benzylamine is used as substrate and the formation of the enzyme product benzaldehyde is measured directly by UV-spectros copy at 250 nm or by HPLC with UV-detection after derivatisation with dinitrophenylhydrazine. Alternatively, C-benzaldehyde produced from C-benzylamine is quantified radiochemically. Furthermore, hydrogen peroxide formed during benzylamine transformation is determined in enzyme-coupled colorimetric or fluorometric assays. Besides, a direct fluorimetric method using a (naphthalene-2-yl)methylamine substrate was published. A disadvantage of the methods using benzylamine as substrate is that this substrate only weakly binds to the enzyme. This property could lead to an overestimation of the inhibitory potency of inhibitors when the assay is performed under competitive conditions. We have recently developed an HPLC/UV-method for evaluation of PAO inhibitors, which uses the new tightly binding substrate 6-(5-phenyl-2H-tetrazol-2-yl)hexan-1-amine. Although the physiological substrates of PAO are not clearly defined presently, it can be assumed that inhibition data are more meaningful applying tightly instead of weakly binding substrates.

In our published PAO assay, we used the enzyme isolated and purified from bovine plasma. Since the supplier of the enzyme could not deliver the product for some time, we now studied, whether bovine plasma itself can be used for inhibitor screening instead of the purified enzyme. With the modified assay the inhibition properties of two known and one new covalent binding PAO inhibitors were compared applying varying incubation conditions to gain more insights into the factors determining PAO inhibition.

Materials and methods

Chemistry

General. Column chromatography was performed on silica gel 60, particle size 0.040–0.063 mm, from Macherey & Nagel (Düren, Germany). The melting point of the target compound was determined on a Büchi B-540 apparatus (Essen, Germany) and is uncorrected. The 1H-NMR and 13C-NMR spectra were recorded on an Agilent DD2 600 spectrometer (600 MHz) (Richardson, TX). The high-resolution mass spectrum (HRMS) was measured on a Bruker

CONTACT Matthias Lehr, lehrm@uni-muenster.de Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Correnstrasse 48, Münster D-48149, Germany

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
micrOTOF-Q II spectrometer (Bremen, Germany) applying atmospheric pressure chemical ionisation (APCI). The purity of 18 was determined by reversed phase HPLC on a Machery & Nagel Nucleosil 100 RP18 column (3 mm inside diameter × 125 mm, particle size 3 μm) (Düren, Germany) at a flow rate of 0.4 mL/min with a gradient consisting of acetonitrile/aqueous TRIS solution (50 mM, pH 8.5 at 20 °C) (5:95 to 90:10, v/v). The sample was prepared by mixing 20 μL of a 5 mM solution of the compound in DMSO with 180 μL of acetonitrile. An aliquot of 5 μL of this solution was injected into the HPLC-system. The temperature of the column oven was 20 °C. UV-absorbance was measured at 254 nm.

2-(3-Phenylphenyl)acetohydrazide (18). Hydrazine monohydrate (273 mg, 5.45 mmol, 265 μL) was added to a solution of ethyl 2-(3-phenylphenyl)acetate34 (140 mg, 0.58 mmol) in ethanol (7 mL) and the mixture was heated to reflux for 42 h. Further amounts of hydrazine monohydrate were added after 19 h (273 mg, 5.45 mmol, 265 μL) and 27 h (273 mg, 5.45 mmol, 265 μL) after cooling the mixture to ambient temperature, the solvent was removed under reduced pressure. The crude product was treated with a small amount of ice-cold ethanol. The precipitate obtained was filtered off by suction and washed twice with ice-cold ethanol to give 18 as a white solid (39 mg, 29%). C7H14N3O2 (226.3); mp 126 °C; 1H-NMR (600 MHz, DMSO-d6): δ (ppm) 3.42 (s, 2H), 4.24 (s, 2H), 7.25 (dt, J = 7.7 Hz and 1.4 Hz, 1H), 7.35–7.40 (m, 2H), 7.45–7.49 (m, 2H), 7.51 (dd, J = 7.7 Hz, 1.9 Hz and 1.1 Hz, 1H), 7.55 (t, J = 1.8 Hz, 1H), 7.61–7.64 (m, 2H), 9.23 (1H); 13C-NMR (151 MHz, DMSO-d6): δ (ppm) 30.55, 124.78, 126.66, 127.42, 127.43, 128.03, 128.80, 128.92, 136.93, 140.14, 140.17, 169.51; HRMS (APCI, direct probe) m/z [M + H]+ calculated: 227,1179, found: 227,1163. Purity (HPLC) 99%.

Biochemistry

Reagents. Heparin-sodium 25,000 I.U./5 mL (Ratiopharm, Ulm, Germany); phosphate buffered saline (PBS) tablets (one tablet dissolved in 200 mL of deionised water yields 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.133 M sodium chloride, pH 7.4 at 25 °C), dimethyl sulfoxide, benzylamine (7), phenamit methanesulfonate salt, cloglirine, selgeline (Sigma-Aldrich, Steinheim, Germany); tris(hydroxymethyl)aminomethane (TRIS) base, benzaldehyde (14) (WVR, Darmstadt, Germany); acetonitrile HPLC-grade (Fischer Scientific, Loughborough, UK); bovine PAO purified from bovine plasma (lyophilised powder, activity: 32 Tabor units/mg protein) (Abnova, Taipei, Taiwan delivered by Biozol, Eching, Germany); ω-(5-phenyl-2H-tetrazol-2-yl)alkanamines 1-6, the corresponding aldehydes 8-13 and the PAO inhibitors 2-(4-phenylphenyl)acetohydrazide (16) and 2-amino-N-(3-phenylbenzyl) acetamide (17) were synthesised as published recently;13,33,35,36 bovine blood was obtained from Coesfelder Fleischhandelsgesellschaft, Bernd Grewe (Coesfeld, Germany).

Isolation of bovine plasma. Immediately after the death of the animal, bovine blood was collected in a 250 mL polypropylene vessel, which contained 5,000 I.U. heparin. The blood was centrifuged in 50 mL Falcon tubes at 1,500 × g for 15 min at room temperature. The plasma supernatant was carefully separated by aspiration and frozen in polypropylene tubes at −20 °C until further use.

Determination of the conversion rates of different amine substrates by bovine plasma. The conversion rates of the amine substrates 1-7 to the corresponding aldehydes 8-14 by bovine plasma was measured as described previously33, with the modification that the solution of the isolated PAO in PBS (0.19 mg/mL) (95 μL) was replaced by PBS (89 μL) and bovine plasma (6 μL).

Determination of the IC50-values of the PAO inhibitor 2-(4-phenylphenyl)acetohydrazide (16) with bovine plasma using different substrates. The IC50-values were measured as described previously (without pre-incubation).33 with the modification that the solution of the isolated PAO in PBS (0.19 mg/mL) (95 μL) was replaced by PBS (89 μL) and bovine plasma (6 μL).

General procedure for inhibitor screening without pre-incubation of bovine plasma with the inhibitor. A mixture of a DMSO solution of 4 (10 mM) (2.5 μL), a DMSO solution of the appropriate inhibitor (concentration variable) (2.5 μL) and PBS buffer (pH 7.4) (89 μL) was treated with bovine plasma (6 μL). After incubation at 37 °C for 45 min, the enzyme reaction was terminated by the addition of acetonitrile (100 μL). The sample was cooled in an ice bath for 10 min and centrifuged at 12,000 × g and 10 °C for 5 min. An aliquot of the supernatant (150 μL) was diluted with aqueous TRIS buffer (100 mM, pH 8.5 at 20 °C) (150 μL), allowed to stand at room temperature for 30 min, and analysed by HPLC. The HPLC–UV-system consisted of a Thermo Scientific Dionex UltiMate 3000 system including an autosampler and a variable wavelength detector (ThermoFisher Scientific, Germering, Germany). Separation was achieved on a Luna 3 u C8(2) analytical column (3 mm inside diameter × 150 mm, particle size 3 μm) (Phenomenex, Aschaffenburg, Germany); tris(hydroxymethyl)aminomethane (TRIS) base, benzaldehyde (14) and benzylamine (7) were carried in the same manner in parallel (n = 3). Furthermore, a blank incubation, in which the enzyme solution was replaced by the buffer used for dissolving the enzyme, was carried out. The relative inhibition values were determined at different inhibitor concentrations and calculated as the ratio of the areas of the 1,3-oxazolidine 15 peaks formed in presence and absence of the test compounds (corrected by the blank value). From these data, the IC50-values were calculated via Probit-log concentration graphs. The experiments using benzylamine (7) as substrate were carried out in the same way with the modifications that aliquots (150 μL)

Table 1 Conversion rates of different amines by purified bovine PAO and by bovine plasma.

| Substrate | Conversion of substrate [%] | Purified PAO | Bovine Plasma |
|-----------|-----------------------------|--------------|--------------|
| 3-(5-Phenyl-2H-tetrazol-2-yl)propan-1-amine (1) | 12 ± 0.8 | 5 ± 0.8 |
| 4-(5-Phenyl-2H-tetrazol-2-yl)butan-1-amine (2) | 55 ± 2.6 | 66 ± 5.6 |
| 5-(5-Phenyl-2H-tetrazol-2-yl)pentan-1-amine (3) | 45 ± 1.3 | 51 ± 4.3 |
| 6-(5-Phenyl-2H-tetrazol-2-yl)hexan-1-amine (4) | 57 ± 1.4 | 51 ± 1.5 |
| 7-(5-Phenyl-2H-tetrazol-2-yl)heptan-1-amine (5) | 30 ± 1.1 | 23 ± 2.1 |
| 8-(5-Phenyl-2H-tetrazol-2-yl)octan-1-amine (6) | 25 ± 1.2 | 26 ± 1.8 |
| Benzylamine (7) | 20 ± 2.1 | 30 ± 2.0 |

*The substrate (250 μM) was incubated with the appropriate enzyme (18 μg purified PAO or 6 μL of bovine plasma) in a final volume of 100 μL. The amount of substrate converted was determined by HPLC with UV detection using solutions of the corresponding enzyme products 8-14 as previously described.33 Values are means ± standard deviations, n = 3.

*Values already published33,35.
Figure 1. Conversion of 6-(5-phenyl-2H-tetrazol-2-yl)hexan-1-amine (4) to 6-(5-phenyl-2H-tetrazol-2-yl)hexanal (11) by PAO and derivatisation of the aliphatic aldehyde product to the 1,3-oxazolidine 15 by TRIS.

![Figure 1](image1.png)

Figure 2. (A) Reversed phase chromatogram of a solution of the substrate 6-(5-phenyl-2H-tetrazol-2-yl)hexan-1-amine (4) (250 μM) treated with bovine plasma (6 μL per 100 μL sample volume). After incubation at 37 °C for 45 min, the enzyme reaction was terminated by addition of acetonitrile. The sample was centrifuged and diluted with an equal amount of aqueous TRIS buffer (100 mM, pH 8.5 at 20 °C). Chromatography was performed on a Luna 3 μm C8(2) analytical column with acetonitrile/aqueous TRIS buffer (50 mM, pH 8.5 at 20 °C) (35:65, v/v) at a flow rate of 0.4 ml/min using a detection wavelength of 238 nm. (B) Reference chromatogram obtained under the same conditions in absence of bovine plasma (blank). 4: Amine substrate; 15: TRIS adduct of aldehyde 11 liberated by the enzyme.
of the supernatants obtained after addition of acetonitrile and centrifugation were diluted with water (150 μL) and acetonitrile/aqueous ammonium acetate solution (10 mM, pH 6) (45:55, v/v) was used as eluent at a detection wavelength of 250 nm.

General procedure for inhibitor screening with pre-incubation of bovine plasma with the inhibitor. To a DMSO solution of the appropriate inhibitor (concentration variable) (2.5 μL) was added a dilution of bovine plasma in PBS (95 μL), prepared by mixing 89 volume parts of PBS with 6 volume parts of bovine plasma. The resulting mixture was pre-incubated at 37 °C for 15 min. Then the incubation was started at 37 °C by addition of a solution of the substrate 4 (10 mM) in DMSO (2.5 μL). After 45 min, the enzyme reaction was terminated by the addition of acetonitrile (100 μL). The samples were further treated and analysed as described above in the inhibition experiments done without pre-incubation. Controls (n = 3) and a blank were prepared analogously. The experiments using benzylamine (7) as substrate were carried out in the same way with the modifications that aliquots (150 μL) of the supernatants obtained after addition of acetonitrile and centrifugation were diluted with water (150 μL), and acetonitrile/aqueous ammonium acetate solution (10 mM, pH 6) (45:55, v/v) was used as eluent at a detection wavelength of 250 nm.

Results and discussion

According to literature, the high amine oxidase activity in bovine plasma is mainly caused by PAO37-40. Other important amine oxidases present in the organism like monoamine oxidase A (MAO A), MAO B, and diamine oxidase (DAO) obviously are not of significant relevance for the cleavage of primary amines in plasma. Therefore, it seemed to be possible to use crude bovine plasma instead of the purified enzyme for the evaluation of PAO inhibitors.

During the development and validation of our published method for the detection of PAO inhibitors using purified bovine PAO33, we tested a series of phenyltetrazolylalkanamines (Table 1) for their usefulness as substrate. The highest conversion rates were found for the 5-phenyl-2H-tetrazol-2-yl-substituted butan-1, pentan-1, and hexan-1-amines 2-4 (Table 1). For the implementation of the assay we chose the hexan-1-amine substrate 4. The product 6-(5-phenyl-2H-tetrazol-2-yl)hexanal (11) produced from this compound by PAO was measured by HPLC with UV-detection. Since this aldehyde product only eluted with poor peak shape due to hydrate formation in the aqueous mobile phase, a pre-column derivatisation with tris(hydroxymethyl)aminomethane (TRIS) leading to the formation of a non-hydratable oxazolidine was carried out before analysis (Figure 1).

In this work, we first evaluated, whether it is possible to achieve similar conversion rates for the substrate 4 as obtained in the isolated enzyme assay using reasonable amounts of bovine plasma instead of the purified PAO. It was found that 6 μL bovine plasma per 100 μL sample volume produced about the same amount of aldehyde 11 as the applied quantity of purified PAO (18 μg in 100 μL sample volume). Figure 2 shows a chromatogram of the TRIS adduct 15 of the enzyme product 11 released by bovine plasma from the hexan-1-amine substrate 4. No significant differences to corresponding chromatograms obtained with the purified PAO at the same detection wavelength (238 nm) could be observed. In particular, interfering peaks resulting from the plasma were not visible at the retention time of the 1,3-oxazolidine.

Next, we tested the conversion rates of the related amines 1-3 and 5-7 by bovine plasma. As shown in Table 1, comparable results were obtained with the purified enzyme and the crude plasma. In both cases, the butane-, pentane-, and hexane-1-amine 2-4 were the best substrates with a conversion rate of about 50%. The longer-chain heptane- and octane-1-amines 5 and 6 were transformed only half as efficiently. Their conversion rates corresponded to that of benzylamine (7), which is often used as substrate in PAO assays. The short-chain propan-1-amine 1 was reacted by both purified PAO and bovine plasma even less (about 5-10% of the maximum possible amount) under the conditions applied.

| Substrate | IC50 (μM) | Purified PAO | Bovine plasma |
|-----------|----------|--------------|---------------|
| 3-(5-Phenylytetraxol2-2-yl)propan-1-amine | 53 ± 3 | n.d. | n.d. |
| 4-(5-Phenylytetraxol2-2-yl)butan-1-amine | 2.5 ± 0.30b | 5.3 ± 0.49 | 2.5 ± 0.30b |
| 5-(5-Phenyl-2H-tetrazol-2-yl)pentan-1-amine | 5.4 ± 0.09b | 9.7 ± 0.78 | 5.4 ± 0.09b |
| 6-(5-Phenyl-2H-tetrazol-2-yl)hexanal-1-amine | 11 ± 1.2b | 17 ± 0.80 | 11 ± 1.2b |
| 7-(5-Phenyl-2H-tetrazol-2-yl)heptan-1-amine | n.d. | n.d. | n.d. |
| 8-(5-Phenyl-2H-tetrazol-2-yl)octan-1-amine | 11 ± 0.83b | 16 ± 3.4 | 11 ± 0.83b |
| Benzylamine (7) | 0.12 ± 0.03b | 0.29 ± 0.07 | 0.29 ± 0.07 |

1Inhibition values obtained without pre-incubation of enzyme and inhibitor; means ± standard deviation (n = 3).
2Values already published33.
3Not determined due to the low conversion rate of 1 in bovine plasma (see Table 1).
4Not determined because the TRIS adduct of the produced aldehyde co-eluted with the inhibitor.

To evaluate the comparability of inhibition data obtained with the purified enzyme and the crude plasma, we measured the inhibition values of the known PAO inhibitor 2-(4-phenylphenyl)acetohydrazide (16) (for formula see Table 3) using the different amine substrates 1-7. In these experiments, the enzyme was added to a solution containing both substrate and inhibitor. Thus, no pre-incubation of enzyme with the inhibitor took place. As shown in Table 2, all IC50-values obtained with the plasma were about twofold higher than the IC50-values determined with the purified enzyme. This may be due to the binding of the inhibitor to plasma proteins leading to a somewhat reduced effective concentration. In addition, consistent differences in the apparent inhibitory potency of the inhibitor 16 in dependence of the substrate applied could be registered for both enzyme preparations. The reason for these fluctuating values lies in strongly different binding affinities of the substrates to the enzyme as discussed recently33. The parallelism of the inhibition values of 16 on using the purified enzyme and the crude plasma is another proof of that PAO is the enzyme in bovine plasma actually responsible for the cleavage of the used substrates.

2-(4-Phenylphenyl)acetohydrazide (16) is known to inhibit PAO by forming covalent bonds with the cofactor topaquinone. Due to this kind of action, we have studied the inhibition of the purified PAO after pre-incubation of the enzyme with the inhibitor. This procedure provides the inhibitor more time for a covalent modification of the enzyme and its cofactor, respectively, which can lead to a higher inhibitory potency. Applying a pre-incubation time of 15 min, actually the IC50-values of 16 against purified PAO using 4 as substrate declined significantly. Furthermore, the pronounced deviation of the inhibition values using 4 and benzylamine, respectively, disappeared. The same effects were observed, when bovine plasma was used (Table 3). Thus, after pre-incubation, the IC50-values for 16 were 0.29 μM (substrate 4) and 0.11 μM (substrate benzylamine) in case of the purified enzyme33, and 0.23 and 0.13 μM in case of the analogous experiments with plasma. These data again prove the comparability of the results of the inhibition experiments obtained with the two enzyme sources.
Recently, it was reported that 2-amino-N-(3-phenylbenzyl)acetamide (17) (Table 3) is a potent covalent inhibitor of PAO. Since we were interested in the inhibitory potency of this compound in comparison to the hydrazide 16, we re-synthesised 17 and evaluated its activity against PAO in bovine plasma. Performing the measurement without pre-incubation of inhibitor and enzyme and using the phenyldiazotetrazolylhexan-1-amine 4 as substrate, the aminoacetamide 17 was about 20-fold more active than the hydrazide 16 (IC_{50}-values 0.86 μM vs. 17 μM). With the substrate benzylamine this alteration levelled (IC_{50}-values 0.087 μM vs. 0.29 μM). Interestingly, when the inhibitors were pre-incubated with the enzyme no significant differences in the potency of the inhibitors could be seen anymore, whichever of both substrates were used. These results can be explained as follows. The hydrazide 16 and the aminoacetamide 17 are selective irreversible inhibitors reacting with the co-substrate topaquinone via their terminal NH\textsubscript{2}-group. Such kind of inhibitors must operate through a two-step mechanism\textsuperscript{11}. First, they bind reversibly to the enzyme forming a non-covalent enzyme-inhibitor complex, which can undergo covalent bond formation in a subsequent second step. Without pre-incubation of inhibitor and enzyme, the inhibitors must first compete with the substrate for a reversible binding to the enzyme. When inhibitor and enzyme are pre-incubated, differences in the reversible binding activity no longer play a pronounced role. More important for the observed potency is the reactivity of the nucleophilic group. Obviously, the inhibitor 17 forms much tighter reversible bonds with the enzyme than the inhibitor 16 and the substrate hexan-1-amine 4 much tighter ones than the substrate benzylamine resulting in the strongly varying IC_{50}-values observed in the experiments without pre-incubation. The inhibition data of 16 and 17 in the pre-incubation experiments indicate that the reactive groups of these compounds possess about the same reactivity leading to similar IC_{50}-values. Next, we synthesised and tested the hydrazide 18, in which the reactive functional residue and the terminal phenyl moiety were arranged in meta-position like in case of the amide 17. Compound 18 showed slightly higher IC_{50}-values than its para-substituted derivative 16 under all test conditions applied (Table 3).

Finally, we wanted to confirm that the amine oxidases MAO A, MAO B, and DAO are not involved in substrate conversion by bovine plasma using specific inhibitors of these enzymes. Under pre-incubation conditions, the MAO A inhibitor clorgiline and MAO B inhibitor seleagine reduced the activity of MAO A and B, respectively,\textsuperscript{35} by more than 95% at a concentration of 0.1 μM. The DAO inhibitor phenamil produced 43% inhibition of DAO at 10 μM. In contrast, neither of these compounds blocked the substrate transformation in the assays with purified PAO as well as with bovine plasma at 10 μM under the same conditions, which again proves the central role of PAO for the degradation of primary amines in bovine plasma.

In conclusion, we have shown that crude bovine plasma can be used for PAO inhibitor screening instead of the purified enzyme. Furthermore, it became evident that the inhibition data (IC_{50}-values) of the tested covalent inhibitors 16–18 strongly depend on the kind of substrate and the incubation conditions used.

### Disclosure statement

The authors report no competing interests.

### Funding

This work has been supported by the Deutsche Forschungsgemeinschaft (DFG; LE 1046/8-1).

### References

1. Finney J, Moon HJ, Ronnebaum T, et al. Human copper-dependent amine oxidases. Arch Biochem Biophys 2014;546:19–32.
2. Lewinsohn R. Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 1984;17:223–56.
3. Stolen CM, Yegutkin GG, Kurkijärvi R, et al. Origins of serum semicarbazide-sensitive amine oxidase. Circ Res 2004;95:50–7.
4. Salmi M, Jalkanen S. Vascular adhesion protein-1: a cell surface amine oxidase in translation. Antioxid Redox Signal 2017. doi:10.1089/ars.2017.7418.
5. Boomsma F, Bhaggoe UM, van der Houwen AM, et al. Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochim Biophys Acta 2003;1647:48–54.
6. Yu PH, Wright S, Fan EH, et al. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta 2003;1647:193–9.
7. Pannecoek R, Serruys D, Benmerjda L, et al. Vascular adhesion protein-1: role in human pathology and application as a biomarker. Crit Rev Clin Lab Sci 2015;52:284–300.

---

**Table 3.** Inhibitory potency of 2-(4-phenylphenyl)acetohydrazide (16), 2-amino-N-(3-phenylbenzyl)acetamide (17) and 2-(3-phenylphenyl)acetohydrazide (18) against PAO in bovine plasma in dependence of the substrate and the assay conditions.

| Conditions and Substrate | Inhibitor IC_{50} (μM)* |
|--------------------------|-------------------------|
| Measurement without pre-incubation of enzyme and inhibitor: | 16 | 17 | 18 |
| Hexan-1-amine 4 | 17 ± 1 | 0.86 ± 0.04 | 20 ± 1 |
| Benzylamine | 0.29 ± 0.07 | 0.087 ± 0.003 | 0.62 ± 0.05 |
| Measurement with pre-incubation of enzyme and inhibitor: | | | |
| Hexan-1-amine 4 | 0.23 ± 0.04 | 0.29 ± 0.03 | 0.38 ± 0.02 |
| Benzylamine | 0.13 ± 0.03 | 0.15 ± 0.01 | 0.24 ± 0.03 |

*aValues are means ± standard deviations, n = 3.
8. Yraola F, Albericio F, Royo M. Inhibition of VAP1: quickly gaining ground as an anti-inflammatory therapy. ChemMedChem 2007;2:173–4.
9. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 2005;5:760–71.
10. Dunkel P, Balogh B, Meleddu R, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat 2011;21:1453–71.
11. Dunkel P, Gelain A, Barlocco D, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. Curr Med Chem 2008;15:1827–39.
12. Tabor CW, Tabor H, Rosenthal SM. Purification of amine oxidase from beef plasma. J Biol Chem 1954;208:645–61.
13. Artico M, Silvestri R, Stefancich G, et al. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. Eur J Med Chem 1992;27:219–28.
14. Lee Y, Ling KQ, Lu X, et al. 3-Pyrroline are mechanisms-based inactivators of the quinone-dependent amine oxidases but only substrates of the flavin-dependent amine oxidases. J Am Chem Soc 2002;124:12135–43.
15. Jeon HB, Sun G, Sayre LM. Inactivation of bovine plasma amine oxidase by 4-arylxy-2-butyamines and related analogs. Biochim Biophys Acta 2003;1647:343–54.
16. Agostinelli E, Palmigiani P, Vedova LD, et al. Interaction of bovine serum amine oxidase with the polyamine oxidase inactivator MLD 72527. Biochem Biophys Res Commun 2006;340:840–4.
17. Tipton KF, Davey G, Motherway M, Monoamine oxidase assays. In: Taylor GP and Sullivan JP, eds. Current protocols in pharmacology. New York: Wiley; 2000. 3.6.1–3.6.42.
18. Li H, Luo W, Lin J, et al. Assay of plasma semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res Commun Chem Pathol Pharmacol 1990;69:71–83.
19. Inoue T, Morita M, Tojo T, et al. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorg Med Chem 2013;21:873–81.
20. Holt A, Sharman DF, Baker GB, et al. A continuous spectrophotometric assay for monooamine oxidase and related enzymes in tissue homogenates. Anal Biochem 1997;244:384–92.
21. Bligt-Lindén E, Pihlavinisto M, Szatmári I, et al. Novel pyridazine-nitrogen inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode. J Med Chem 2013;56:9837–48.
22. Nurminen EM, Pihlavinisto M, Lázár L, et al. Synthesis, in vitro activity, and three-dimensional quantitative structure-activity relationship of novel hydrazine inhibitors of human vascular adhesion protein-1. J Med Chem 2010;53:6301–15.
23. Olivieri A, Tipton K. Inhibition of bovine plasma semicarbazide-sensitive amine oxidase by caffeine. J Biochem Mol Toxicol 2011;25:26–7.